# KPV peptide dosage in the research literature | KPV Compound

> KPV peptide dosage as reported in preclinical studies: ~10 nM in vitro, ~100 uM in drinking water in mice, 1-10 mg/mL topical eye drops in rabbits. No validated human dose exists. Research context only.

Concentrations and routes pulled straight from the cell and animal literature. No human protocol has been validated, so nothing here is a dosing recommendation.

## Before the details

Here is the honest frame for KPV peptide dosage: every number on this page comes from cells in a dish or from animals, and none of it is a human dose. Researchers used very small amounts — billionths to millionths of a mole — in cell studies, dosed mice through their drinking water, and dripped it onto rabbit eyes. There is no validated human dose, no human pharmacokinetics, and no schedule a person should follow. The peptide also breaks down fast on its own, which is why a lot of recent work wraps it in protective particles. We report what was measured; we do not recommend doses.

## KPV dosing in the research literature

Reported KPV peptide dosage spans three rough tiers, each tied to a model. In cell culture, activity appeared at nanomolar concentrations — about 10 nM in intestinal epithelial and immune cells — extending up to low-micromolar (0.1-10 uM) in other cell systems [1][6]. In mouse colitis, KPV was delivered at roughly 100 uM in drinking water by the oral route [1]. For topical work, rabbit corneal studies used 1, 5, or 10 mg/mL eye drops (30 uL drops, four times daily for four days) [6]. There is no established or validated human research dose [1].

These figures describe experiments, not protocols. The wide gap between a 10 nM in-vitro concentration and a 100 uM in-vivo drinking-water concentration is instructive: it largely reflects delivery losses across the gut rather than a difference in intrinsic potency, and it is not a human-relevant range [1]. The in-vitro figure is the cleaner read on how little KPV a cell needs once the peptide actually reaches it — nanomolar — while the in-vivo drinking-water figure is what had to be supplied at the mouth to get enough intact peptide to the colon [1]. That gap is exactly the problem the delivery-chemistry literature was built to close [5].

## Half-life, stability, and why formulation dominates the field

As a small unprotected tripeptide, KPV is expected to be rapidly degraded by peptidases, and no validated human pharmacokinetic half-life has been published [1]. Free KPV is susceptible to enzymatic breakdown in the gastrointestinal tract and serum — a real obstacle for any oral delivery [1]. This is the single biggest reason the recent literature is dominated by delivery chemistry rather than dose-finding: if the peptide does not survive long enough to reach the target, the nominal dose tells you little [1].

The formulation toolkit is broad. Hyaluronic-acid nanoparticles, polysaccharide and double-network hydrogels, and self-assembled carrier-free nanodrugs have all been built to stabilize the peptide and target inflamed tissue via PepT1 [5]. In one such study, orally delivered hyaluronic-acid-functionalized KPV nanoparticles (about 272 nm) embedded in a chitosan/alginate hydrogel reduced colitis severity more effectively than non-targeted formulations, downregulating TNF-alpha and accelerating mucosal healing [5]. A 2024 PepT1-targeted nanodrug took the same idea further, co-assembling KPV with the immunosuppressant FK506 and improving both acute and chronic colitis while restoring tight-junction proteins [15]. Structural chemistry is part of the toolkit too: reductive glycoalkylation of the lysine residue has been used to tune KPV's physicochemical properties for analog and formulation design [11].

The practical takeaway for reading any KPV dose is that route and formulation matter as much as the number. A milligram-per-milliliter figure on a rabbit eye drop, a micromolar figure in mouse drinking water, and a nanomolar figure in a dish are answering three different delivery questions, none of which maps onto a human regimen [1][6].

---

A two-sided reading of the KPV tripeptide record — the PepT1 gut-uptake and NF-kB findings logged to source on one plane, the research-only FDA status held plainly on the other; no clinic behind the seam and nothing here dispensed or sold.